Clinical Trials

92 enrolled

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05963074 2026-06-05

TAILOR

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02427620 2026-05-22

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

131 enrolled

Lymphoma, Mantle-Cell

NCT03646461 2026-05-22

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Phase 2 Terminated

5 enrolled 9 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06271616 2026-05-22

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Phase 2 Terminated

2 enrolled

Bronchiolitis Obliterans Syndrome

NCT02007044 2026-05-20

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

66 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT04802590 2026-05-20

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

210 enrolled

Lymphoma, Mantle-Cell

NCT03710772 2026-05-19

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT01841723 2026-05-13

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Other hematologic neoplasm

44 enrolled

Leukemia, Hairy Cell

NCT06649812 2026-05-13

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

120 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04263480 2026-05-12

CZAR-1

99 enrolled

Waldenstrom Macroglobulinemia, Neoplasms

NCT04273139 2026-05-11

Ibrutinib + Venetoclax in Untreated WM

45 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT03506373 2026-05-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 2 Terminated

21 enrolled 11 charts

Waldenstrom Macroglobulinemia

NCT01849263 2026-04-30

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

41 enrolled 12 charts

Lymphoma, Follicular

NCT02581930 2026-04-30

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

18 enrolled 10 charts

Dermatologic

Melanoma

NCT01500733 2026-04-28

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

86 enrolled 10 charts

Leukemia, Leukemia, Lymphoid, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02436707 2026-04-20

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

129 enrolled

Lymphoma

NCT02514083 2026-04-14

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

29 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05998642 2026-04-14

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

30 enrolled

Lymphoma, Non-Hodgkin

NCT01589302 2026-04-13

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

154 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT04450173 2026-04-13

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

40 enrolled

Lymphoma, Follicular

NCT03478514 2026-04-09

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

39 enrolled

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03697512 2026-04-08

MALIBU

175 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT02997761 2026-04-07

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

Phase 2 Completed

19 enrolled

Burkitt Lymphoma

NCT02518555 2026-04-06

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Completed

42 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02682641 2026-03-27

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

50 enrolled

Lymphoma, Mantle-Cell

NCT03282396 2026-03-20

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

20 enrolled